Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal de...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/1/77 |
| _version_ | 1827666473870426112 |
|---|---|
| author | Maritza P. Garrido Allison N. Fredes Lorena Lobos-González Manuel Valenzuela-Valderrama Daniela B. Vera Carmen Romero |
| author_facet | Maritza P. Garrido Allison N. Fredes Lorena Lobos-González Manuel Valenzuela-Valderrama Daniela B. Vera Carmen Romero |
| author_sort | Maritza P. Garrido |
| collection | DOAJ |
| description | Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal debulking surgery following chemotherapy with platinum/gemcitabine and taxane compounds. During the last years, anti-angiogenic therapy and poly adenosine diphosphate-ribose polymerases (PARP)-inhibitors were introduced in therapeutic schemes. Several studies have shown that these drugs increase the progression-free survival and overall survival of patients with ovarian cancer, but the identification of patients who have the greatest benefits is still under investigation. In the present review, we discuss about the molecular characteristics of the disease, the recent evidence of approved treatments and the new possible complementary approaches, focusing on drug repurposing, non-coding RNAs, and nanomedicine as a new method for drug delivery. |
| first_indexed | 2024-03-10T01:52:10Z |
| format | Article |
| id | doaj.art-9bbe90957e1840848a5fb1392ea7904e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T01:52:10Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-9bbe90957e1840848a5fb1392ea7904e2023-11-23T13:03:24ZengMDPI AGBiomedicines2227-90592021-12-011017710.3390/biomedicines10010077Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian CancerMaritza P. Garrido0Allison N. Fredes1Lorena Lobos-González2Manuel Valenzuela-Valderrama3Daniela B. Vera4Carmen Romero5Laboratorio de Endocrinología y Biología de la Reproducción, Hospital Clínico Universidad de Chile, Santiago 8380456, ChileLaboratorio de Endocrinología y Biología de la Reproducción, Hospital Clínico Universidad de Chile, Santiago 8380456, ChileCentro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago 7710162, ChileLaboratorio de Microbiología Celular, Instituto de Investigación y Postgrado, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8320000, ChileLaboratorio de Endocrinología y Biología de la Reproducción, Hospital Clínico Universidad de Chile, Santiago 8380456, ChileLaboratorio de Endocrinología y Biología de la Reproducción, Hospital Clínico Universidad de Chile, Santiago 8380456, ChileEpithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal debulking surgery following chemotherapy with platinum/gemcitabine and taxane compounds. During the last years, anti-angiogenic therapy and poly adenosine diphosphate-ribose polymerases (PARP)-inhibitors were introduced in therapeutic schemes. Several studies have shown that these drugs increase the progression-free survival and overall survival of patients with ovarian cancer, but the identification of patients who have the greatest benefits is still under investigation. In the present review, we discuss about the molecular characteristics of the disease, the recent evidence of approved treatments and the new possible complementary approaches, focusing on drug repurposing, non-coding RNAs, and nanomedicine as a new method for drug delivery.https://www.mdpi.com/2227-9059/10/1/77epithelial ovarian cancerdrug repurposingnon-coding RNAsnanocarriersanti-angiogenic therapy |
| spellingShingle | Maritza P. Garrido Allison N. Fredes Lorena Lobos-González Manuel Valenzuela-Valderrama Daniela B. Vera Carmen Romero Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer Biomedicines epithelial ovarian cancer drug repurposing non-coding RNAs nanocarriers anti-angiogenic therapy |
| title | Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer |
| title_full | Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer |
| title_fullStr | Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer |
| title_full_unstemmed | Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer |
| title_short | Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer |
| title_sort | current treatments and new possible complementary therapies for epithelial ovarian cancer |
| topic | epithelial ovarian cancer drug repurposing non-coding RNAs nanocarriers anti-angiogenic therapy |
| url | https://www.mdpi.com/2227-9059/10/1/77 |
| work_keys_str_mv | AT maritzapgarrido currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer AT allisonnfredes currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer AT lorenalobosgonzalez currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer AT manuelvalenzuelavalderrama currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer AT danielabvera currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer AT carmenromero currenttreatmentsandnewpossiblecomplementarytherapiesforepithelialovariancancer |